Daily Stock Setups

Aurobindo Pharma gets USFDA nod for anti-depressant drug

Posted on: Wed, 04 Mar 2009 21:41:00 EST

Symbols: AUBPF

Are you looking to increase your ETF knowledge?

Mumbai, Mar 04, 2009 (Asia Pulse Data Source via COMTEX) --
AUBPF | Quote | Chart | News | PowerRating -- Drug-maker Aurobindo Pharma today said it has received tentative approval from the US drug regulator for anti-depressant tablets Escitalopram Oxalate.

In a filing with the Bombay Stock Exchange, Aurobindo Pharma said it got tentative approval from the US Food and Drug Administration (USFDA) for Escitalopram Oxalate tablets.

Escitalopram Oxalate tablets are the generic version of Forest Laboratories' Lexapro used in treating patients suffering from depression and mood disorders, it added.

Escitalopram Oxalate tablets will be available in 5 mg, 10 mg and 20 mg.

Aurobindo now has 92 approved Abbreviated New Drug Application (ANDA) from the USFDA.

Shares of the company were trading at Rs 160.40, up 2.79 per cent on the BSE.

For full details on (AUBPF) AUBPF. (AUBPF) has Short Term PowerRatings at TradingMarkets. Details on (AUBPF) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Related News

AUROBINDO PHARMA USA, INC. 65IB - DRUGS, PHARMACEUTICALS AND HEMATOLOGY PRODUCTS - 01/12/10
Aurobindo Pharma wins Australian approval for depression drug - 12/18/09
Aurobindo Pharma wins FDA approval for generic allergic rhinitis drug - 12/18/09
Australian authorities okay indian firm's depression drug - 12/16/09
AUROBINDO UNIT GETS AUSTRALIA NOD FOR ANTI-DEPRESSION DRUG - 12/16/09
More News >>

UPCOMING EVENTS

Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.

Thursday February 11 04:30 PM

Leveraged ETF Trading Course

Thursday February 11 12:30 PM

Hear What Kevin Haggerty Sees in the Stock Market Today!

Wednesday February 10 01:00 PM

Hear What Gary Kaltbaum Sees in the Stock Market Today!

* Attendance is strictly limited and are filled on a first-come, first-served basis.

PREMIER SPONSORED LINKS

TRADE CENTER

Recent Articles Market Analysis Stock Alerts Breaking News All News

About TradingMarkets Advertise Contact Careers Link to Us Help Terms & Conditions Privacy Policy Return Policy Testimonials Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.